Legend Biotech Announces Proposed $225M Public Offering of ADSs
LEGN sits 92% above its 52-week low of $16.24.
Summary
Legend Biotech announced a proposed $225 million underwritten public offering of American Depositary Shares, with underwriters having a 30-day option to purchase an additional 15%. This capital raise follows a period of strong positive clinical data for its CAR-T therapies and robust sales growth for CARVYKTI, as highlighted in recent SEC filings and news. While the offering provides significant funding for the company's active pipeline and commercialization efforts, it will dilute existing shareholders and increase share supply, likely creating short-term downward pressure on the stock.
At the time of this announcement, LEGN was trading at $31.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $16.24 to $45.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.